TWiV reviews the new nomenclature for SARS-CoV-2 variants, effectiveness of Pfizer/BioNTech vaccine against variants, modified Moderna vaccine against variants, impact of COVID-19 interventions on influenza in China and the US, and binding of RaTG13 spike protein to ACE2 of multiple species.
TWiV reviews the difficulties in predicting species susceptibility to SARS-CoV-2 infection by only examining the ACE2 protein, and the olfactory mucosa as a portal of entry into the central nervous system in COVID-19 patients.
Daniel Griffin provides a clinical report on COVID-19, then we discuss Bill Foege’s letter to CDC director Robert Redfield, the false promise of herd immunity for COVID-19, secret blueprints for SARS-CoV-2 vaccine trials released, and neuropilin-1 as a possible entry protein for the virus.
Daniel Griffin provides a clinical update on COVID-19, then Ralph Baric joins TWiV to discuss SARS-CoV-2 transmission, vaccines, diagnostic tests, and a new animal model from his laboratory that does not use transgenic mice.
Vincent, Kathy and Rich discuss COVID-19 research paper overload, Moderna’s mRNA vaccine Phase I results, increase of ACE2 RNA by cigarette smoke, and answer listener questions.
The TWiV team returns this week to SARS-CoV-2019 coverage to review the latest epi curves, the fatality rate, furin cleavage site and receptor binding domain in the spike glycoprotein, related CoV recovered from pangolins, evidence that the virus did not escape from a laboratory, and many more questions sent in by listeners.
Matt joins the TWiV team to discuss the discovery of a SARS-like coronavirus in bats that can infect human cells, and what is going on with MERS-coronavirus.